nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluorouracil—Nucleic Acid Synthesis Inhibitors—Capecitabine—esophageal cancer	0.342	1	CiPCiCtD
Fluorouracil—TYMP—esophageal cancer	0.114	0.757	CbGaD
Fluorouracil—head and neck cancer—esophageal cancer	0.0922	0.388	CtDrD
Fluorouracil—stomach cancer—esophageal cancer	0.0753	0.317	CtDrD
Fluorouracil—DPYD—Capecitabine—esophageal cancer	0.0706	0.354	CbGbCtD
Fluorouracil—pancreatic cancer—esophageal cancer	0.0702	0.295	CtDrD
Fluorouracil—TYMP—Capecitabine—esophageal cancer	0.0469	0.235	CbGbCtD
Fluorouracil—CYP2A6—esophageal cancer	0.0365	0.242	CbGaD
Fluorouracil—TYMS—Capecitabine—esophageal cancer	0.025	0.125	CbGbCtD
Fluorouracil—ABCC5—Cisplatin—esophageal cancer	0.0104	0.0519	CbGbCtD
Fluorouracil—MTHFR—Methotrexate—esophageal cancer	0.00959	0.048	CbGbCtD
Fluorouracil—TYMS—Methotrexate—esophageal cancer	0.00817	0.0409	CbGbCtD
Fluorouracil—ABCC3—Cisplatin—esophageal cancer	0.00652	0.0327	CbGbCtD
Fluorouracil—ABCC3—Methotrexate—esophageal cancer	0.00423	0.0212	CbGbCtD
Fluorouracil—SLC22A7—Methotrexate—esophageal cancer	0.00331	0.0166	CbGbCtD
Fluorouracil—ABCC4—Methotrexate—esophageal cancer	0.00324	0.0162	CbGbCtD
Fluorouracil—ABCG2—Carboplatin—esophageal cancer	0.00314	0.0157	CbGbCtD
Fluorouracil—ABCG2—Cisplatin—esophageal cancer	0.00268	0.0134	CbGbCtD
Fluorouracil—CYP2C9—Capecitabine—esophageal cancer	0.00198	0.0099	CbGbCtD
Fluorouracil—ABCG2—Methotrexate—esophageal cancer	0.00174	0.00871	CbGbCtD
Fluorouracil—ALB—Methotrexate—esophageal cancer	0.0012	0.00601	CbGbCtD
Fluorouracil—Ocular toxicity—Cisplatin—esophageal cancer	0.00101	0.0459	CcSEcCtD
Fluorouracil—CYP2C9—Cisplatin—esophageal cancer	0.000996	0.00499	CbGbCtD
Fluorouracil—Gastrointestinal ulcer haemorrhage—Cisplatin—esophageal cancer	0.00071	0.0324	CcSEcCtD
Fluorouracil—Nail changes—Capecitabine—esophageal cancer	0.000691	0.0316	CcSEcCtD
Fluorouracil—UMPS—bronchus—esophageal cancer	0.00066	0.0547	CbGeAlD
Fluorouracil—UPP1—bronchus—esophageal cancer	0.000606	0.0502	CbGeAlD
Fluorouracil—Neutropenic sepsis—Capecitabine—esophageal cancer	0.000578	0.0264	CcSEcCtD
Fluorouracil—UPP1—trachea—esophageal cancer	0.000544	0.045	CbGeAlD
Fluorouracil—Extravasation—Carboplatin—esophageal cancer	0.000532	0.0243	CcSEcCtD
Fluorouracil—Nail changes—Methotrexate—esophageal cancer	0.000514	0.0235	CcSEcCtD
Fluorouracil—UMPS—digestive system—esophageal cancer	0.00051	0.0423	CbGeAlD
Fluorouracil—DPYD—bronchus—esophageal cancer	0.000492	0.0407	CbGeAlD
Fluorouracil—Fibrosis—Cisplatin—esophageal cancer	0.000476	0.0218	CcSEcCtD
Fluorouracil—UPP1—digestive system—esophageal cancer	0.000468	0.0387	CbGeAlD
Fluorouracil—Memory loss—Cisplatin—esophageal cancer	0.000463	0.0212	CcSEcCtD
Fluorouracil—Superinfection—Capecitabine—esophageal cancer	0.000442	0.0202	CcSEcCtD
Fluorouracil—UMPS—lung—esophageal cancer	0.000426	0.0353	CbGeAlD
Fluorouracil—MTHFR—neck—esophageal cancer	0.0004	0.0331	CbGeAlD
Fluorouracil—UPP1—lung—esophageal cancer	0.000391	0.0324	CbGeAlD
Fluorouracil—Gastrointestinal ulcer haemorrhage—Methotrexate—esophageal cancer	0.000389	0.0178	CcSEcCtD
Fluorouracil—Fibrosis—Capecitabine—esophageal cancer	0.000351	0.016	CcSEcCtD
Fluorouracil—Speech impairment NOS—Methotrexate—esophageal cancer	0.000342	0.0156	CcSEcCtD
Fluorouracil—DPYD—lung—esophageal cancer	0.000317	0.0263	CbGeAlD
Fluorouracil—Telangiectasia—Methotrexate—esophageal cancer	0.000317	0.0145	CcSEcCtD
Fluorouracil—Scab—Capecitabine—esophageal cancer	0.000315	0.0144	CcSEcCtD
Fluorouracil—Slurred speech—Cisplatin—esophageal cancer	0.000304	0.0139	CcSEcCtD
Fluorouracil—UMPS—lymph node—esophageal cancer	0.000291	0.0241	CbGeAlD
Fluorouracil—Myelosuppression—Cisplatin—esophageal cancer	0.00029	0.0133	CcSEcCtD
Fluorouracil—TYMP—bronchus—esophageal cancer	0.000285	0.0236	CbGeAlD
Fluorouracil—TYMP—smooth muscle tissue—esophageal cancer	0.000279	0.0231	CbGeAlD
Fluorouracil—PPAT—lung—esophageal cancer	0.000275	0.0227	CbGeAlD
Fluorouracil—MTHFR—bronchus—esophageal cancer	0.000268	0.0222	CbGeAlD
Fluorouracil—UPP1—lymph node—esophageal cancer	0.000267	0.0221	CbGeAlD
Fluorouracil—Congenital anomaly—Capecitabine—esophageal cancer	0.000264	0.0121	CcSEcCtD
Fluorouracil—Developmental delay—Capecitabine—esophageal cancer	0.000264	0.0121	CcSEcCtD
Fluorouracil—Fibrosis—Methotrexate—esophageal cancer	0.000261	0.0119	CcSEcCtD
Fluorouracil—TYMP—trachea—esophageal cancer	0.000256	0.0212	CbGeAlD
Fluorouracil—TYMS—bronchus—esophageal cancer	0.000244	0.0202	CbGeAlD
Fluorouracil—TYMS—smooth muscle tissue—esophageal cancer	0.000239	0.0198	CbGeAlD
Fluorouracil—ABCC5—bronchus—esophageal cancer	0.000239	0.0198	CbGeAlD
Fluorouracil—Dysaesthesia—Capecitabine—esophageal cancer	0.000232	0.0106	CcSEcCtD
Fluorouracil—Febrile neutropenia—Cisplatin—esophageal cancer	0.000226	0.0103	CcSEcCtD
Fluorouracil—TYMP—digestive system—esophageal cancer	0.00022	0.0182	CbGeAlD
Fluorouracil—SLC22A7—digestive system—esophageal cancer	0.000219	0.0182	CbGeAlD
Fluorouracil—SLC29A1—bronchus—esophageal cancer	0.000219	0.0182	CbGeAlD
Fluorouracil—DPYD—lymph node—esophageal cancer	0.000217	0.018	CbGeAlD
Fluorouracil—MTHFR—digestive system—esophageal cancer	0.000207	0.0171	CbGeAlD
Fluorouracil—SLC29A1—trachea—esophageal cancer	0.000197	0.0163	CbGeAlD
Fluorouracil—Sudden death—Capecitabine—esophageal cancer	0.000196	0.00896	CcSEcCtD
Fluorouracil—Cardiomyopathy—Capecitabine—esophageal cancer	0.000196	0.00896	CcSEcCtD
Fluorouracil—TYMS—digestive system—esophageal cancer	0.000189	0.0156	CbGeAlD
Fluorouracil—PPAT—lymph node—esophageal cancer	0.000188	0.0156	CbGeAlD
Fluorouracil—TYMP—lung—esophageal cancer	0.000184	0.0152	CbGeAlD
Fluorouracil—Balance disorder—Capecitabine—esophageal cancer	0.000183	0.00838	CcSEcCtD
Fluorouracil—Necrosis—Cisplatin—esophageal cancer	0.000173	0.00792	CcSEcCtD
Fluorouracil—MTHFR—lung—esophageal cancer	0.000173	0.0143	CbGeAlD
Fluorouracil—Pericarditis—Methotrexate—esophageal cancer	0.000173	0.00789	CcSEcCtD
Fluorouracil—SLC29A1—digestive system—esophageal cancer	0.000169	0.014	CbGeAlD
Fluorouracil—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000169	0.00771	CcSEcCtD
Fluorouracil—Febrile neutropenia—Capecitabine—esophageal cancer	0.000167	0.00762	CcSEcCtD
Fluorouracil—ABCC4—bronchus—esophageal cancer	0.000165	0.0137	CbGeAlD
Fluorouracil—Infection—Carboplatin—esophageal cancer	0.000164	0.00751	CcSEcCtD
Fluorouracil—TYMS—lung—esophageal cancer	0.000158	0.0131	CbGeAlD
Fluorouracil—Encephalopathy—Capecitabine—esophageal cancer	0.000156	0.00714	CcSEcCtD
Fluorouracil—Tenderness—Cisplatin—esophageal cancer	0.000156	0.00713	CcSEcCtD
Fluorouracil—Extravasation—Cisplatin—esophageal cancer	0.000156	0.00713	CcSEcCtD
Fluorouracil—ABCC3—digestive system—esophageal cancer	0.000155	0.0128	CbGeAlD
Fluorouracil—Nail disorder—Capecitabine—esophageal cancer	0.000155	0.00707	CcSEcCtD
Fluorouracil—ABCC5—lung—esophageal cancer	0.000154	0.0128	CbGeAlD
Fluorouracil—Cellulitis—Cisplatin—esophageal cancer	0.00015	0.00684	CcSEcCtD
Fluorouracil—Sudden death—Methotrexate—esophageal cancer	0.000146	0.00667	CcSEcCtD
Fluorouracil—Ulcer—Cisplatin—esophageal cancer	0.000144	0.00657	CcSEcCtD
Fluorouracil—Dysarthria—Cisplatin—esophageal cancer	0.000144	0.00657	CcSEcCtD
Fluorouracil—Pain—Carboplatin—esophageal cancer	0.000141	0.00647	CcSEcCtD
Fluorouracil—SLC29A1—lung—esophageal cancer	0.000141	0.0117	CbGeAlD
Fluorouracil—Blister—Capecitabine—esophageal cancer	0.000139	0.00636	CcSEcCtD
Fluorouracil—CYP2A6—lung—esophageal cancer	0.000138	0.0114	CbGeAlD
Fluorouracil—Body temperature increased—Carboplatin—esophageal cancer	0.000131	0.00598	CcSEcCtD
Fluorouracil—ABCC3—lung—esophageal cancer	0.000129	0.0107	CbGeAlD
Fluorouracil—ABCC4—digestive system—esophageal cancer	0.000128	0.0106	CbGeAlD
Fluorouracil—TYMP—lymph node—esophageal cancer	0.000126	0.0104	CbGeAlD
Fluorouracil—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000125	0.00574	CcSEcCtD
Fluorouracil—Tingling sensation—Capecitabine—esophageal cancer	0.000125	0.0057	CcSEcCtD
Fluorouracil—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000125	0.0057	CcSEcCtD
Fluorouracil—Febrile neutropenia—Methotrexate—esophageal cancer	0.000124	0.00567	CcSEcCtD
Fluorouracil—MTHFR—lymph node—esophageal cancer	0.000118	0.00979	CbGeAlD
Fluorouracil—Eye irritation—Capecitabine—esophageal cancer	0.000117	0.00537	CcSEcCtD
Fluorouracil—Encephalopathy—Methotrexate—esophageal cancer	0.000116	0.00532	CcSEcCtD
Fluorouracil—Nail disorder—Methotrexate—esophageal cancer	0.000115	0.00526	CcSEcCtD
Fluorouracil—Cellulitis—Capecitabine—esophageal cancer	0.00011	0.00504	CcSEcCtD
Fluorouracil—Herpes simplex—Capecitabine—esophageal cancer	0.000109	0.00497	CcSEcCtD
Fluorouracil—Lacrimation increased—Capecitabine—esophageal cancer	0.000109	0.00497	CcSEcCtD
Fluorouracil—TYMS—lymph node—esophageal cancer	0.000108	0.00893	CbGeAlD
Fluorouracil—ABCC4—lung—esophageal cancer	0.000107	0.00884	CbGeAlD
Fluorouracil—Dysarthria—Capecitabine—esophageal cancer	0.000106	0.00485	CcSEcCtD
Fluorouracil—Ulcer—Capecitabine—esophageal cancer	0.000106	0.00485	CcSEcCtD
Fluorouracil—ABCC5—lymph node—esophageal cancer	0.000105	0.00873	CbGeAlD
Fluorouracil—Amnesia—Cisplatin—esophageal cancer	0.000105	0.0048	CcSEcCtD
Fluorouracil—Inflammation—Capecitabine—esophageal cancer	0.000103	0.00473	CcSEcCtD
Fluorouracil—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	9.87e-05	0.00451	CcSEcCtD
Fluorouracil—SLC29A1—lymph node—esophageal cancer	9.67e-05	0.00801	CbGeAlD
Fluorouracil—Necrosis—Methotrexate—esophageal cancer	9.51e-05	0.00435	CcSEcCtD
Fluorouracil—Irritability—Cisplatin—esophageal cancer	9.42e-05	0.00431	CcSEcCtD
Fluorouracil—Oesophagitis—Capecitabine—esophageal cancer	9.16e-05	0.00419	CcSEcCtD
Fluorouracil—ABCC3—lymph node—esophageal cancer	8.85e-05	0.00733	CbGeAlD
Fluorouracil—Nasopharyngitis—Cisplatin—esophageal cancer	8.83e-05	0.00404	CcSEcCtD
Fluorouracil—Sepsis—Capecitabine—esophageal cancer	8.7e-05	0.00398	CcSEcCtD
Fluorouracil—CYP1A2—digestive system—esophageal cancer	8.69e-05	0.00719	CbGeAlD
Fluorouracil—Speech disorder—Methotrexate—esophageal cancer	8.68e-05	0.00397	CcSEcCtD
Fluorouracil—Extravasation—Methotrexate—esophageal cancer	8.56e-05	0.00391	CcSEcCtD
Fluorouracil—Thrombophlebitis—Capecitabine—esophageal cancer	8.41e-05	0.00384	CcSEcCtD
Fluorouracil—Photosensitivity—Capecitabine—esophageal cancer	8.29e-05	0.00379	CcSEcCtD
Fluorouracil—Swelling—Capecitabine—esophageal cancer	8.25e-05	0.00377	CcSEcCtD
Fluorouracil—CYP2C9—digestive system—esophageal cancer	8.24e-05	0.00683	CbGeAlD
Fluorouracil—Pancytopenia—Cisplatin—esophageal cancer	8.1e-05	0.00371	CcSEcCtD
Fluorouracil—Herpes simplex—Methotrexate—esophageal cancer	8.1e-05	0.0037	CcSEcCtD
Fluorouracil—Dysarthria—Methotrexate—esophageal cancer	7.89e-05	0.00361	CcSEcCtD
Fluorouracil—Ulcer—Methotrexate—esophageal cancer	7.89e-05	0.00361	CcSEcCtD
Fluorouracil—Amnesia—Capecitabine—esophageal cancer	7.75e-05	0.00354	CcSEcCtD
Fluorouracil—Inflammation—Methotrexate—esophageal cancer	7.7e-05	0.00352	CcSEcCtD
Fluorouracil—Dermatitis bullous—Capecitabine—esophageal cancer	7.62e-05	0.00348	CcSEcCtD
Fluorouracil—ALB—lymph node—esophageal cancer	7.54e-05	0.00625	CbGeAlD
Fluorouracil—ABCG2—lung—esophageal cancer	7.54e-05	0.00624	CbGeAlD
Fluorouracil—Acute coronary syndrome—Cisplatin—esophageal cancer	7.5e-05	0.00343	CcSEcCtD
Fluorouracil—Myocardial infarction—Cisplatin—esophageal cancer	7.46e-05	0.00341	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Cisplatin—esophageal cancer	7.46e-05	0.00341	CcSEcCtD
Fluorouracil—Cardiac failure—Capecitabine—esophageal cancer	7.46e-05	0.00341	CcSEcCtD
Fluorouracil—Lethargy—Capecitabine—esophageal cancer	7.43e-05	0.0034	CcSEcCtD
Fluorouracil—Stomatitis—Cisplatin—esophageal cancer	7.42e-05	0.00339	CcSEcCtD
Fluorouracil—Conjunctivitis—Cisplatin—esophageal cancer	7.4e-05	0.00338	CcSEcCtD
Fluorouracil—ABCC4—lymph node—esophageal cancer	7.3e-05	0.00605	CbGeAlD
Fluorouracil—Osteoarthritis—Capecitabine—esophageal cancer	7.28e-05	0.00333	CcSEcCtD
Fluorouracil—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	7.28e-05	0.00333	CcSEcCtD
Fluorouracil—CYP1A2—lung—esophageal cancer	7.25e-05	0.00601	CbGeAlD
Fluorouracil—Irritability—Capecitabine—esophageal cancer	6.95e-05	0.00318	CcSEcCtD
Fluorouracil—Cardiac arrest—Capecitabine—esophageal cancer	6.92e-05	0.00316	CcSEcCtD
Fluorouracil—Ataxia—Capecitabine—esophageal cancer	6.84e-05	0.00313	CcSEcCtD
Fluorouracil—Coma—Methotrexate—esophageal cancer	6.82e-05	0.00312	CcSEcCtD
Fluorouracil—Dry skin—Capecitabine—esophageal cancer	6.67e-05	0.00305	CcSEcCtD
Fluorouracil—Nasopharyngitis—Capecitabine—esophageal cancer	6.51e-05	0.00298	CcSEcCtD
Fluorouracil—Sepsis—Methotrexate—esophageal cancer	6.48e-05	0.00296	CcSEcCtD
Fluorouracil—Muscular weakness—Capecitabine—esophageal cancer	6.42e-05	0.00293	CcSEcCtD
Fluorouracil—Dysphagia—Capecitabine—esophageal cancer	6.29e-05	0.00288	CcSEcCtD
Fluorouracil—Thrombophlebitis—Methotrexate—esophageal cancer	6.26e-05	0.00286	CcSEcCtD
Fluorouracil—Photosensitivity—Methotrexate—esophageal cancer	6.17e-05	0.00282	CcSEcCtD
Fluorouracil—Angina pectoris—Capecitabine—esophageal cancer	6.13e-05	0.0028	CcSEcCtD
Fluorouracil—Arrhythmia—Cisplatin—esophageal cancer	6.1e-05	0.00279	CcSEcCtD
Fluorouracil—Alopecia—Cisplatin—esophageal cancer	6.04e-05	0.00276	CcSEcCtD
Fluorouracil—Pancytopenia—Capecitabine—esophageal cancer	5.97e-05	0.00273	CcSEcCtD
Fluorouracil—Erythema—Cisplatin—esophageal cancer	5.95e-05	0.00272	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Capecitabine—esophageal cancer	5.85e-05	0.00267	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Capecitabine—esophageal cancer	5.74e-05	0.00263	CcSEcCtD
Fluorouracil—Pneumonia—Capecitabine—esophageal cancer	5.64e-05	0.00258	CcSEcCtD
Fluorouracil—Infestation—Capecitabine—esophageal cancer	5.61e-05	0.00256	CcSEcCtD
Fluorouracil—Infestation NOS—Capecitabine—esophageal cancer	5.61e-05	0.00256	CcSEcCtD
Fluorouracil—Vision blurred—Cisplatin—esophageal cancer	5.6e-05	0.00256	CcSEcCtD
Fluorouracil—Acute coronary syndrome—Capecitabine—esophageal cancer	5.53e-05	0.00253	CcSEcCtD
Fluorouracil—Lethargy—Methotrexate—esophageal cancer	5.53e-05	0.00253	CcSEcCtD
Fluorouracil—Myocardial infarction—Capecitabine—esophageal cancer	5.5e-05	0.00251	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Capecitabine—esophageal cancer	5.5e-05	0.00251	CcSEcCtD
Fluorouracil—Anaemia—Cisplatin—esophageal cancer	5.5e-05	0.00251	CcSEcCtD
Fluorouracil—Stomatitis—Capecitabine—esophageal cancer	5.47e-05	0.0025	CcSEcCtD
Fluorouracil—Urinary tract infection—Capecitabine—esophageal cancer	5.45e-05	0.00249	CcSEcCtD
Fluorouracil—Conjunctivitis—Capecitabine—esophageal cancer	5.45e-05	0.00249	CcSEcCtD
Fluorouracil—Osteoarthritis—Methotrexate—esophageal cancer	5.42e-05	0.00248	CcSEcCtD
Fluorouracil—Leukopenia—Cisplatin—esophageal cancer	5.32e-05	0.00243	CcSEcCtD
Fluorouracil—Epistaxis—Capecitabine—esophageal cancer	5.29e-05	0.00242	CcSEcCtD
Fluorouracil—Agranulocytosis—Capecitabine—esophageal cancer	5.23e-05	0.00239	CcSEcCtD
Fluorouracil—Irritability—Methotrexate—esophageal cancer	5.17e-05	0.00236	CcSEcCtD
Fluorouracil—ABCG2—lymph node—esophageal cancer	5.16e-05	0.00427	CbGeAlD
Fluorouracil—Convulsion—Cisplatin—esophageal cancer	5.15e-05	0.00236	CcSEcCtD
Fluorouracil—Ataxia—Methotrexate—esophageal cancer	5.1e-05	0.00233	CcSEcCtD
Fluorouracil—Myalgia—Cisplatin—esophageal cancer	5.06e-05	0.00231	CcSEcCtD
Fluorouracil—Haemoglobin—Capecitabine—esophageal cancer	5.06e-05	0.00231	CcSEcCtD
Fluorouracil—Rhinitis—Capecitabine—esophageal cancer	5.05e-05	0.00231	CcSEcCtD
Fluorouracil—Haemorrhage—Capecitabine—esophageal cancer	5.04e-05	0.0023	CcSEcCtD
Fluorouracil—Hypoaesthesia—Capecitabine—esophageal cancer	5.01e-05	0.00229	CcSEcCtD
Fluorouracil—Discomfort—Cisplatin—esophageal cancer	5e-05	0.00229	CcSEcCtD
Fluorouracil—Pharyngitis—Capecitabine—esophageal cancer	5e-05	0.00228	CcSEcCtD
Fluorouracil—Anaphylactic shock—Cisplatin—esophageal cancer	4.85e-05	0.00222	CcSEcCtD
Fluorouracil—Oedema—Cisplatin—esophageal cancer	4.85e-05	0.00222	CcSEcCtD
Fluorouracil—Infection—Cisplatin—esophageal cancer	4.82e-05	0.0022	CcSEcCtD
Fluorouracil—Nervous system disorder—Cisplatin—esophageal cancer	4.76e-05	0.00218	CcSEcCtD
Fluorouracil—Thrombocytopenia—Cisplatin—esophageal cancer	4.75e-05	0.00217	CcSEcCtD
Fluorouracil—Tachycardia—Cisplatin—esophageal cancer	4.74e-05	0.00217	CcSEcCtD
Fluorouracil—Eosinophilia—Methotrexate—esophageal cancer	4.64e-05	0.00212	CcSEcCtD
Fluorouracil—Anorexia—Cisplatin—esophageal cancer	4.63e-05	0.00211	CcSEcCtD
Fluorouracil—Hypotension—Cisplatin—esophageal cancer	4.53e-05	0.00207	CcSEcCtD
Fluorouracil—Arrhythmia—Capecitabine—esophageal cancer	4.5e-05	0.00206	CcSEcCtD
Fluorouracil—Alopecia—Capecitabine—esophageal cancer	4.45e-05	0.00203	CcSEcCtD
Fluorouracil—Pancytopenia—Methotrexate—esophageal cancer	4.45e-05	0.00203	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Cisplatin—esophageal cancer	4.42e-05	0.00202	CcSEcCtD
Fluorouracil—Erythema—Capecitabine—esophageal cancer	4.38e-05	0.002	CcSEcCtD
Fluorouracil—Paraesthesia—Cisplatin—esophageal cancer	4.36e-05	0.00199	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Methotrexate—esophageal cancer	4.35e-05	0.00199	CcSEcCtD
Fluorouracil—Dyspnoea—Cisplatin—esophageal cancer	4.33e-05	0.00198	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Methotrexate—esophageal cancer	4.27e-05	0.00195	CcSEcCtD
Fluorouracil—Decreased appetite—Cisplatin—esophageal cancer	4.22e-05	0.00193	CcSEcCtD
Fluorouracil—Pneumonia—Methotrexate—esophageal cancer	4.2e-05	0.00192	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Cisplatin—esophageal cancer	4.19e-05	0.00192	CcSEcCtD
Fluorouracil—Infestation NOS—Methotrexate—esophageal cancer	4.18e-05	0.00191	CcSEcCtD
Fluorouracil—Infestation—Methotrexate—esophageal cancer	4.18e-05	0.00191	CcSEcCtD
Fluorouracil—Pain—Cisplatin—esophageal cancer	4.15e-05	0.0019	CcSEcCtD
Fluorouracil—Vision blurred—Capecitabine—esophageal cancer	4.13e-05	0.00189	CcSEcCtD
Fluorouracil—Stomatitis—Methotrexate—esophageal cancer	4.07e-05	0.00186	CcSEcCtD
Fluorouracil—Conjunctivitis—Methotrexate—esophageal cancer	4.06e-05	0.00186	CcSEcCtD
Fluorouracil—Anaemia—Capecitabine—esophageal cancer	4.05e-05	0.00185	CcSEcCtD
Fluorouracil—Feeling abnormal—Cisplatin—esophageal cancer	4e-05	0.00183	CcSEcCtD
Fluorouracil—Epistaxis—Methotrexate—esophageal cancer	3.94e-05	0.0018	CcSEcCtD
Fluorouracil—Leukopenia—Capecitabine—esophageal cancer	3.92e-05	0.00179	CcSEcCtD
Fluorouracil—Agranulocytosis—Methotrexate—esophageal cancer	3.9e-05	0.00178	CcSEcCtD
Fluorouracil—Body temperature increased—Cisplatin—esophageal cancer	3.84e-05	0.00175	CcSEcCtD
Fluorouracil—Haemoglobin—Methotrexate—esophageal cancer	3.77e-05	0.00172	CcSEcCtD
Fluorouracil—Haemorrhage—Methotrexate—esophageal cancer	3.75e-05	0.00171	CcSEcCtD
Fluorouracil—Myalgia—Capecitabine—esophageal cancer	3.73e-05	0.00171	CcSEcCtD
Fluorouracil—Chest pain—Capecitabine—esophageal cancer	3.73e-05	0.00171	CcSEcCtD
Fluorouracil—Pharyngitis—Methotrexate—esophageal cancer	3.72e-05	0.0017	CcSEcCtD
Fluorouracil—Discomfort—Capecitabine—esophageal cancer	3.69e-05	0.00169	CcSEcCtD
Fluorouracil—Confusional state—Capecitabine—esophageal cancer	3.61e-05	0.00165	CcSEcCtD
Fluorouracil—Oedema—Capecitabine—esophageal cancer	3.58e-05	0.00164	CcSEcCtD
Fluorouracil—Hypersensitivity—Cisplatin—esophageal cancer	3.58e-05	0.00163	CcSEcCtD
Fluorouracil—Infection—Capecitabine—esophageal cancer	3.55e-05	0.00162	CcSEcCtD
Fluorouracil—Nervous system disorder—Capecitabine—esophageal cancer	3.51e-05	0.0016	CcSEcCtD
Fluorouracil—Thrombocytopenia—Capecitabine—esophageal cancer	3.5e-05	0.0016	CcSEcCtD
Fluorouracil—Tachycardia—Capecitabine—esophageal cancer	3.49e-05	0.0016	CcSEcCtD
Fluorouracil—Anorexia—Capecitabine—esophageal cancer	3.41e-05	0.00156	CcSEcCtD
Fluorouracil—Hypotension—Capecitabine—esophageal cancer	3.34e-05	0.00153	CcSEcCtD
Fluorouracil—Diarrhoea—Cisplatin—esophageal cancer	3.32e-05	0.00152	CcSEcCtD
Fluorouracil—Alopecia—Methotrexate—esophageal cancer	3.31e-05	0.00151	CcSEcCtD
Fluorouracil—Erythema—Methotrexate—esophageal cancer	3.26e-05	0.00149	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Capecitabine—esophageal cancer	3.26e-05	0.00149	CcSEcCtD
Fluorouracil—Insomnia—Capecitabine—esophageal cancer	3.24e-05	0.00148	CcSEcCtD
Fluorouracil—Paraesthesia—Capecitabine—esophageal cancer	3.21e-05	0.00147	CcSEcCtD
Fluorouracil—Dyspnoea—Capecitabine—esophageal cancer	3.19e-05	0.00146	CcSEcCtD
Fluorouracil—Dyspepsia—Capecitabine—esophageal cancer	3.15e-05	0.00144	CcSEcCtD
Fluorouracil—Decreased appetite—Capecitabine—esophageal cancer	3.11e-05	0.00142	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Capecitabine—esophageal cancer	3.09e-05	0.00141	CcSEcCtD
Fluorouracil—Vomiting—Cisplatin—esophageal cancer	3.09e-05	0.00141	CcSEcCtD
Fluorouracil—Vision blurred—Methotrexate—esophageal cancer	3.08e-05	0.00141	CcSEcCtD
Fluorouracil—Rash—Cisplatin—esophageal cancer	3.06e-05	0.0014	CcSEcCtD
Fluorouracil—Pain—Capecitabine—esophageal cancer	3.06e-05	0.0014	CcSEcCtD
Fluorouracil—Dermatitis—Cisplatin—esophageal cancer	3.06e-05	0.0014	CcSEcCtD
Fluorouracil—Anaemia—Methotrexate—esophageal cancer	3.02e-05	0.00138	CcSEcCtD
Fluorouracil—Feeling abnormal—Capecitabine—esophageal cancer	2.95e-05	0.00135	CcSEcCtD
Fluorouracil—Leukopenia—Methotrexate—esophageal cancer	2.92e-05	0.00134	CcSEcCtD
Fluorouracil—Nausea—Cisplatin—esophageal cancer	2.88e-05	0.00132	CcSEcCtD
Fluorouracil—Urticaria—Capecitabine—esophageal cancer	2.84e-05	0.0013	CcSEcCtD
Fluorouracil—Body temperature increased—Capecitabine—esophageal cancer	2.83e-05	0.00129	CcSEcCtD
Fluorouracil—Convulsion—Methotrexate—esophageal cancer	2.83e-05	0.00129	CcSEcCtD
Fluorouracil—Chest pain—Methotrexate—esophageal cancer	2.78e-05	0.00127	CcSEcCtD
Fluorouracil—Myalgia—Methotrexate—esophageal cancer	2.78e-05	0.00127	CcSEcCtD
Fluorouracil—Discomfort—Methotrexate—esophageal cancer	2.74e-05	0.00125	CcSEcCtD
Fluorouracil—Confusional state—Methotrexate—esophageal cancer	2.69e-05	0.00123	CcSEcCtD
Fluorouracil—Anaphylactic shock—Methotrexate—esophageal cancer	2.66e-05	0.00122	CcSEcCtD
Fluorouracil—Infection—Methotrexate—esophageal cancer	2.65e-05	0.00121	CcSEcCtD
Fluorouracil—Hypersensitivity—Capecitabine—esophageal cancer	2.64e-05	0.0012	CcSEcCtD
Fluorouracil—Nervous system disorder—Methotrexate—esophageal cancer	2.61e-05	0.00119	CcSEcCtD
Fluorouracil—Thrombocytopenia—Methotrexate—esophageal cancer	2.61e-05	0.00119	CcSEcCtD
Fluorouracil—Anorexia—Methotrexate—esophageal cancer	2.54e-05	0.00116	CcSEcCtD
Fluorouracil—Pruritus—Capecitabine—esophageal cancer	2.53e-05	0.00116	CcSEcCtD
Fluorouracil—Hypotension—Methotrexate—esophageal cancer	2.49e-05	0.00114	CcSEcCtD
Fluorouracil—Diarrhoea—Capecitabine—esophageal cancer	2.45e-05	0.00112	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Methotrexate—esophageal cancer	2.43e-05	0.00111	CcSEcCtD
Fluorouracil—Insomnia—Methotrexate—esophageal cancer	2.41e-05	0.0011	CcSEcCtD
Fluorouracil—Paraesthesia—Methotrexate—esophageal cancer	2.39e-05	0.00109	CcSEcCtD
Fluorouracil—Dyspnoea—Methotrexate—esophageal cancer	2.37e-05	0.00109	CcSEcCtD
Fluorouracil—Somnolence—Methotrexate—esophageal cancer	2.37e-05	0.00108	CcSEcCtD
Fluorouracil—Dizziness—Capecitabine—esophageal cancer	2.37e-05	0.00108	CcSEcCtD
Fluorouracil—Dyspepsia—Methotrexate—esophageal cancer	2.34e-05	0.00107	CcSEcCtD
Fluorouracil—Decreased appetite—Methotrexate—esophageal cancer	2.32e-05	0.00106	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Methotrexate—esophageal cancer	2.3e-05	0.00105	CcSEcCtD
Fluorouracil—Pain—Methotrexate—esophageal cancer	2.28e-05	0.00104	CcSEcCtD
Fluorouracil—Vomiting—Capecitabine—esophageal cancer	2.27e-05	0.00104	CcSEcCtD
Fluorouracil—Rash—Capecitabine—esophageal cancer	2.26e-05	0.00103	CcSEcCtD
Fluorouracil—Dermatitis—Capecitabine—esophageal cancer	2.25e-05	0.00103	CcSEcCtD
Fluorouracil—Headache—Capecitabine—esophageal cancer	2.24e-05	0.00102	CcSEcCtD
Fluorouracil—Feeling abnormal—Methotrexate—esophageal cancer	2.19e-05	0.001	CcSEcCtD
Fluorouracil—Nausea—Capecitabine—esophageal cancer	2.13e-05	0.000971	CcSEcCtD
Fluorouracil—Urticaria—Methotrexate—esophageal cancer	2.12e-05	0.000967	CcSEcCtD
Fluorouracil—Body temperature increased—Methotrexate—esophageal cancer	2.11e-05	0.000962	CcSEcCtD
Fluorouracil—Hypersensitivity—Methotrexate—esophageal cancer	1.96e-05	0.000897	CcSEcCtD
Fluorouracil—Pruritus—Methotrexate—esophageal cancer	1.88e-05	0.000861	CcSEcCtD
Fluorouracil—Diarrhoea—Methotrexate—esophageal cancer	1.82e-05	0.000833	CcSEcCtD
Fluorouracil—Dizziness—Methotrexate—esophageal cancer	1.76e-05	0.000805	CcSEcCtD
Fluorouracil—Vomiting—Methotrexate—esophageal cancer	1.69e-05	0.000774	CcSEcCtD
Fluorouracil—Rash—Methotrexate—esophageal cancer	1.68e-05	0.000768	CcSEcCtD
Fluorouracil—Dermatitis—Methotrexate—esophageal cancer	1.68e-05	0.000767	CcSEcCtD
Fluorouracil—Headache—Methotrexate—esophageal cancer	1.67e-05	0.000763	CcSEcCtD
Fluorouracil—Nausea—Methotrexate—esophageal cancer	1.58e-05	0.000723	CcSEcCtD
Fluorouracil—ABCC5—Disease—NOS2—esophageal cancer	2.38e-06	6.63e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	2.37e-06	6.61e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—NOTCH1—esophageal cancer	2.36e-06	6.57e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CA2—esophageal cancer	2.36e-06	6.57e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CA2—esophageal cancer	2.34e-06	6.53e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—ALDOB—esophageal cancer	2.33e-06	6.49e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—GNG7—esophageal cancer	2.33e-06	6.49e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.3e-06	6.42e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.29e-06	6.38e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—CYP19A1—esophageal cancer	2.25e-06	6.28e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—GAPDH—esophageal cancer	2.24e-06	6.25e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—CRABP1—esophageal cancer	2.22e-06	6.19e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.2e-06	6.14e-05	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—PIK3CA—esophageal cancer	2.2e-06	6.14e-05	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—PIK3CA—esophageal cancer	2.2e-06	6.14e-05	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—MYC—esophageal cancer	2.2e-06	6.14e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—NOS3—esophageal cancer	2.2e-06	6.12e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PLCE1—esophageal cancer	2.19e-06	6.1e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ADH7—esophageal cancer	2.19e-06	6.1e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—ALDH2—esophageal cancer	2.18e-06	6.08e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ADH7—esophageal cancer	2.18e-06	6.07e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PLCE1—esophageal cancer	2.18e-06	6.07e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.17e-06	6.03e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.15e-06	6e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—ABL1—esophageal cancer	2.14e-06	5.96e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—CREBBP—esophageal cancer	2.14e-06	5.95e-05	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—EP300—esophageal cancer	2.12e-06	5.91e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—GNG7—esophageal cancer	2.11e-06	5.89e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—BLVRB—esophageal cancer	2.11e-06	5.87e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—SLC52A3—esophageal cancer	2.11e-06	5.87e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CA1—esophageal cancer	2.1e-06	5.84e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—SLC10A2—esophageal cancer	2.1e-06	5.84e-05	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—EP300—esophageal cancer	2.08e-06	5.81e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—GSTT1—esophageal cancer	2.07e-06	5.78e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—HMOX1—esophageal cancer	2.06e-06	5.73e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—CREBBP—esophageal cancer	2.06e-06	5.73e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—ERBB2—esophageal cancer	2.06e-06	5.73e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—CYP2A6—esophageal cancer	2.05e-06	5.71e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.02e-06	5.62e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—PTGS2—esophageal cancer	2.01e-06	5.6e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—ALDH2—esophageal cancer	1.98e-06	5.52e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—ABCB1—esophageal cancer	1.97e-06	5.5e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—PTGS1—esophageal cancer	1.94e-06	5.42e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—ENO1—esophageal cancer	1.94e-06	5.42e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.94e-06	5.41e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ADH1B—esophageal cancer	1.92e-06	5.35e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CA2—esophageal cancer	1.92e-06	5.34e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—PSME2—esophageal cancer	1.92e-06	5.34e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—PSME1—esophageal cancer	1.92e-06	5.34e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—NOS3—esophageal cancer	1.91e-06	5.33e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ADH1B—esophageal cancer	1.91e-06	5.32e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—GSTT1—esophageal cancer	1.88e-06	5.25e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.88e-06	5.25e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.87e-06	5.22e-05	CbGpPWpGaD
Fluorouracil—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.87e-06	5.21e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—NOS3—esophageal cancer	1.84e-06	5.13e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—TYMP—esophageal cancer	1.84e-06	5.12e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—TYMP—esophageal cancer	1.83e-06	5.09e-05	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—TP53—esophageal cancer	1.81e-06	5.04e-05	CbGpPWpGaD
Fluorouracil—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.79e-06	5e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CA1—esophageal cancer	1.79e-06	4.99e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—SLC10A2—esophageal cancer	1.79e-06	4.99e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—CREBBP—esophageal cancer	1.79e-06	4.99e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—ERBB2—esophageal cancer	1.79e-06	4.99e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CYP26A1—esophageal cancer	1.79e-06	4.98e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PLCE1—esophageal cancer	1.78e-06	4.97e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ADH7—esophageal cancer	1.78e-06	4.97e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CYP26A1—esophageal cancer	1.78e-06	4.95e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—PTGS1—esophageal cancer	1.77e-06	4.92e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—ENO1—esophageal cancer	1.77e-06	4.92e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.76e-06	4.91e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—CDKN1A—esophageal cancer	1.76e-06	4.9e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—PTGS2—esophageal cancer	1.75e-06	4.88e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ALOX15—esophageal cancer	1.74e-06	4.85e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—PSME2—esophageal cancer	1.74e-06	4.85e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—PSME1—esophageal cancer	1.74e-06	4.85e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ALOX15—esophageal cancer	1.73e-06	4.82e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—PTGS2—esophageal cancer	1.68e-06	4.69e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—EP300—esophageal cancer	1.67e-06	4.66e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—TPI1—esophageal cancer	1.66e-06	4.63e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—GSTO1—esophageal cancer	1.66e-06	4.63e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—CYP1B1—esophageal cancer	1.65e-06	4.61e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—TPI1—esophageal cancer	1.65e-06	4.6e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—GSTO1—esophageal cancer	1.65e-06	4.6e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CA2—esophageal cancer	1.64e-06	4.57e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—NOS3—esophageal cancer	1.6e-06	4.47e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.6e-06	4.46e-05	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—CREBBP—esophageal cancer	1.59e-06	4.44e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ALDOB—esophageal cancer	1.59e-06	4.44e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ALDOB—esophageal cancer	1.58e-06	4.41e-05	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—PIK3CA—esophageal cancer	1.57e-06	4.37e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.56e-06	4.36e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—CYP19A1—esophageal cancer	1.55e-06	4.33e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—NOS2—esophageal cancer	1.54e-06	4.3e-05	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—PIK3CA—esophageal cancer	1.54e-06	4.3e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—GAPDH—esophageal cancer	1.53e-06	4.27e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—CDKN1A—esophageal cancer	1.53e-06	4.26e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.52e-06	4.25e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ADH7—esophageal cancer	1.52e-06	4.25e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—GAPDH—esophageal cancer	1.52e-06	4.25e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CRABP1—esophageal cancer	1.52e-06	4.23e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CRABP1—esophageal cancer	1.51e-06	4.21e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.51e-06	4.2e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—CYP1B1—esophageal cancer	1.5e-06	4.18e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—TYMP—esophageal cancer	1.49e-06	4.16e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.49e-06	4.16e-05	CbGpPWpGaD
Fluorouracil—ABCC4—Hemostasis—TP53—esophageal cancer	1.49e-06	4.16e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—PTGS2—esophageal cancer	1.47e-06	4.08e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—MYC—esophageal cancer	1.46e-06	4.06e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—EP300—esophageal cancer	1.46e-06	4.06e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.45e-06	4.05e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—GNG7—esophageal cancer	1.44e-06	4.02e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—GNG7—esophageal cancer	1.44e-06	4e-05	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—NOS3—esophageal cancer	1.43e-06	3.98e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—EGFR—esophageal cancer	1.43e-06	3.97e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—HMOX1—esophageal cancer	1.42e-06	3.95e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.42e-06	3.95e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—CYP19A1—esophageal cancer	1.41e-06	3.93e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—EP300—esophageal cancer	1.4e-06	3.9e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—CREBBP—esophageal cancer	1.38e-06	3.86e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—ABCB1—esophageal cancer	1.36e-06	3.79e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.35e-06	3.77e-05	CbGpPWpGaD
Fluorouracil—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.35e-06	3.77e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.35e-06	3.77e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—TPI1—esophageal cancer	1.35e-06	3.77e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ALDH2—esophageal cancer	1.35e-06	3.75e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.34e-06	3.72e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—CREBBP—esophageal cancer	1.32e-06	3.68e-05	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—PTGS2—esophageal cancer	1.31e-06	3.64e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.3e-06	3.61e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.29e-06	3.59e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.29e-06	3.59e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—GSTT1—esophageal cancer	1.28e-06	3.57e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—TYMP—esophageal cancer	1.28e-06	3.56e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.27e-06	3.55e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—MYC—esophageal cancer	1.27e-06	3.53e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.27e-06	3.53e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CYP2A6—esophageal cancer	1.27e-06	3.53e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.26e-06	3.51e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.25e-06	3.48e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.24e-06	3.46e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—EGFR—esophageal cancer	1.24e-06	3.46e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—NOS3—esophageal cancer	1.24e-06	3.45e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—PIK3CA—esophageal cancer	1.24e-06	3.45e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.24e-06	3.45e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.24e-06	3.44e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—EP300—esophageal cancer	1.22e-06	3.4e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.21e-06	3.37e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ENO1—esophageal cancer	1.21e-06	3.36e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.21e-06	3.36e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PTGS1—esophageal cancer	1.2e-06	3.34e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ENO1—esophageal cancer	1.2e-06	3.34e-05	CbGpPWpGaD
Fluorouracil—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.2e-06	3.34e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PSME2—esophageal cancer	1.19e-06	3.31e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PSME1—esophageal cancer	1.19e-06	3.31e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PSME2—esophageal cancer	1.18e-06	3.29e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PSME1—esophageal cancer	1.18e-06	3.29e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—NOS3—esophageal cancer	1.18e-06	3.29e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—GNG7—esophageal cancer	1.18e-06	3.28e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.15e-06	3.22e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—TPI1—esophageal cancer	1.15e-06	3.22e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.11e-06	3.08e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.1e-06	3.07e-05	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—EP300—esophageal cancer	1.09e-06	3.03e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—PTGS2—esophageal cancer	1.08e-06	3.01e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—PIK3CA—esophageal cancer	1.08e-06	3e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.07e-06	2.97e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.06e-06	2.94e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.05e-06	2.92e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.04e-06	2.89e-05	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—PIK3CA—esophageal cancer	1.04e-06	2.89e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.04e-06	2.89e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.03e-06	2.88e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.03e-06	2.87e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.03e-06	2.86e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CYP1B1—esophageal cancer	1.02e-06	2.84e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—GNG7—esophageal cancer	1e-06	2.8e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ENO1—esophageal cancer	9.82e-07	2.74e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PTGS1—esophageal cancer	9.82e-07	2.74e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PSME1—esophageal cancer	9.68e-07	2.7e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PSME2—esophageal cancer	9.68e-07	2.7e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CYP19A1—esophageal cancer	9.65e-07	2.69e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CYP19A1—esophageal cancer	9.59e-07	2.67e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—EP300—esophageal cancer	9.43e-07	2.63e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ALDH2—esophageal cancer	9.41e-07	2.62e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—CREBBP—esophageal cancer	9.1e-07	2.53e-05	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—PIK3CA—esophageal cancer	9.02e-07	2.51e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—EP300—esophageal cancer	8.99e-07	2.5e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—GSTT1—esophageal cancer	8.95e-07	2.49e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CYP2A6—esophageal cancer	8.85e-07	2.47e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.82e-07	2.46e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—HMOX1—esophageal cancer	8.8e-07	2.45e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—HMOX1—esophageal cancer	8.75e-07	2.44e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.63e-07	2.41e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.59e-07	2.39e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.45e-07	2.35e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—ABCB1—esophageal cancer	8.45e-07	2.35e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—ABCB1—esophageal cancer	8.4e-07	2.34e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PTGS1—esophageal cancer	8.39e-07	2.34e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ENO1—esophageal cancer	8.39e-07	2.34e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CYP1B1—esophageal cancer	8.35e-07	2.33e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PSME2—esophageal cancer	8.27e-07	2.3e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PSME1—esophageal cancer	8.27e-07	2.3e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—CREBBP—esophageal cancer	8.27e-07	2.3e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—NOS3—esophageal cancer	8.15e-07	2.27e-05	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—PIK3CA—esophageal cancer	8.03e-07	2.24e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CYP19A1—esophageal cancer	7.85e-07	2.19e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—PTGS2—esophageal cancer	7.45e-07	2.08e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—NOS3—esophageal cancer	7.4e-07	2.06e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.22e-07	2.01e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—HMOX1—esophageal cancer	7.16e-07	2e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CYP1B1—esophageal cancer	7.13e-07	1.99e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.03e-07	1.96e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—PIK3CA—esophageal cancer	6.98e-07	1.94e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—ABCB1—esophageal cancer	6.88e-07	1.92e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—PTGS2—esophageal cancer	6.77e-07	1.89e-05	CbGpPWpGaD
Fluorouracil—ALB—Hemostasis—TP53—esophageal cancer	6.75e-07	1.88e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CYP19A1—esophageal cancer	6.71e-07	1.87e-05	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—PIK3CA—esophageal cancer	6.65e-07	1.85e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.39e-07	1.78e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.35e-07	1.77e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—EP300—esophageal cancer	6.2e-07	1.73e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—HMOX1—esophageal cancer	6.12e-07	1.71e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6e-07	1.67e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.88e-07	1.64e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—CREBBP—esophageal cancer	5.65e-07	1.57e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—EP300—esophageal cancer	5.63e-07	1.57e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—CREBBP—esophageal cancer	5.61e-07	1.56e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.2e-07	1.45e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—NOS3—esophageal cancer	5.06e-07	1.41e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—NOS3—esophageal cancer	5.03e-07	1.4e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PTGS2—esophageal cancer	4.62e-07	1.29e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PTGS2—esophageal cancer	4.6e-07	1.28e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.6e-07	1.28e-05	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—PIK3CA—esophageal cancer	4.58e-07	1.28e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.44e-07	1.24e-05	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—PIK3CA—esophageal cancer	4.16e-07	1.16e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—NOS3—esophageal cancer	4.11e-07	1.15e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.93e-07	1.09e-05	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—EP300—esophageal cancer	3.85e-07	1.07e-05	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—EP300—esophageal cancer	3.82e-07	1.07e-05	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.76e-07	1.05e-05	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—NOS3—esophageal cancer	3.52e-07	9.8e-06	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.22e-07	8.96e-06	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—EP300—esophageal cancer	3.13e-07	8.72e-06	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.84e-07	7.93e-06	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—PIK3CA—esophageal cancer	2.83e-07	7.88e-06	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—EP300—esophageal cancer	2.67e-07	7.45e-06	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.32e-07	6.45e-06	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.98e-07	5.51e-06	CbGpPWpGaD
